18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma

Riccardo Laudicella; Guido Davidzon; Shreyas Vasanawala; Sergio Baldari; Andrei Iagaru

doi:10.1007/s13139-019-00597-8

¹⁸F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma

Nucl Med Mol Imaging. 2019 Aug;53(4):296-299. doi: 10.1007/s13139-019-00597-8. Epub 2019 Jun 12.

Authors

Riccardo Laudicella¹, Guido Davidzon², Shreyas Vasanawala³, Sergio Baldari¹, Andrei Iagaru²

Affiliations

¹ 1Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.
² 2Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, USA.
³ 3Department of Radiology, Stanford University, Stanford, USA.

Abstract

We described the clinical impact of ¹⁸F-FDG PET/MR in refining the evaluation of a 39-year-old female with newly diagnosed metastatic urethral adenocarcinoma. We detailed the diagnostic imaging workup focusing our attention on the CT, MR, and ¹⁸F-FDG PET/MR different findings. In this case, ¹⁸F-FDG PET/MR imaging evaluation resulted not only effective but also altered staging and spared additional invasive procedures in the assessment of a metastatic urethral adenocarcinoma. Combining a highly sensitive PET with the increase tissue resolution of MR (PET/MR) may improve abdominal and pelvic lesion detection outperforming PET/CT for this indication.

Keywords: 18F-FDG; CT; MR; PET/CT; PET/MR; Urethral adenocarcinoma.